Optimizing the Use of Novel Therapies for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) — June 19, 2026, Houston, TX

A CME/MOC-Accredited Interactive Grand Rounds Series

Date
Friday, June 19, 2026

Program Schedule — Central Time
11:30 AM – 12:00 PM — Registration and Lunch
12:00 PM – 1:00 PM — Educational Program

Location
Houston Methodist Hospital
6445 Main Street
Houston, TX 77030

Meeting Room
OPC 24th Floor Room 316

Faculty

Christopher Flowers

MD, MS, FASCO

The University of Texas MD Anderson Cancer Center, Houston, Texas

Division Head, Division of Cancer Medicine, Chair, Professor, Department of Lymphoma/Myeloma, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large b-cell lymphoma (DLBCL).

I am a:

Clinician / healthcare professional

Other / industry professional

Name(Required)

First Last

Email(Required)

Address(Required)

City State / Province / Region Country

Degree(Required)

Specialty(Required)

If you are a clinician, which of the following best describes your practice setting?(Required)

National Provider Identifier (NPI) Number

These activities are supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pfizer Inc.